Literature DB >> 28029307

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

Christopher B Weldon1, Arin L Madenci1, Sosipatros A Boikos1, Katherine A Janeway1, Suzanne George1, Margaret von Mehren1, Alberto S Pappo1, Joshua D Schiffman1, Jennifer Wright1, Jonathan C Trent1, Karel Pacak1, Constantine A Stratakis1, Lee J Helman1, Michael P La Quaglia1.   

Abstract

Purpose Wild-type gastrointestinal stromal tumors (WT-GISTs) that lack KIT or PDGFRA mutations represent a unique subtype of GIST that predominantly affects children. We sought to determine the effect on event-free survival (EFS) of staging variables, extent of resection, and repeat resection of tumors. Methods In 2008, a WT-GIST clinic was established at the National Cancer Institute, allowing the development of a large clinical database. We included participants who underwent resection of WT-GIST. Associations with EFS (ie, freedom from disease progression or recurrence) were evaluated using the Kaplan-Meier method and Cox proportional hazards modeling. Results Among 76 participants with WT-GISTs, the median follow-up was 4.1 years. Overall EFS (± SE) was 72.6 ± 5.4% at 1 year, 57.6 ± 6.2% at 2 years, 23.7 ± 6.0% at 5 years, and 16.3 ± 5.5% at 10 years postoperatively. Hazard of disease progression or recurrence was significantly increased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas there was no significant effect of negative microscopic resection margins (AHR, 0.9; 95% CI, 0.4 to 2.2; P = 0.86). There was no association between type of gastric resection (ie, anatomic v partial/wedge) and EFS ( P = .67). Repeated resection after the initial resection was significantly associated with decreasing postoperative EFS ( P < .01). Five patients (6%) died after initial enrollment in 2008. Conclusion WT-GIST is an indolent disease, and most patients survive with disease progression. We found no improvement in EFS with more extensive or serial resections. Disease progression or recurrence may be more closely related to tumor biology than surgical management. These data suggest that resections for WT-GISTs be restricted to the initial procedure and that subsequent resections be performed only to address symptoms such as obstruction or bleeding.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28029307      PMCID: PMC5455315          DOI: 10.1200/JCO.2016.68.6733

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

Authors:  Martin D McCarter; Cristina R Antonescu; Karla V Ballman; Robert G Maki; Peter W T Pisters; George D Demetri; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Linda McCall; David M Ota; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2012-07       Impact factor: 6.113

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Pediatric gastrointestinal stromal tumor.

Authors:  Katherine A Janeway; Christopher B Weldon
Journal:  Semin Pediatr Surg       Date:  2012-02       Impact factor: 2.754

4.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors.

Authors:  J P Pierie; U Choudry; A Muzikansky; B Y Yeap; W W Souba; M J Ott
Journal:  Arch Surg       Date:  2001-04

5.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

6.  Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection.

Authors:  Junichi Nishimura; Kiyokazu Nakajima; Takeshi Omori; Tsuyoshi Takahashi; Akiko Nishitani; Toshinori Ito; Toshirou Nishida
Journal:  Surg Endosc       Date:  2006-12-16       Impact factor: 4.584

Review 7.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

8.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

Authors:  Katherine A Janeway; Bernadette Liegl; Amy Harlow; Claudia Le; Antonio Perez-Atayde; Harry Kozakewich; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

Review 10.  Pediatric gastrointestinal stromal tumors.

Authors:  Alberto S Pappo; Katherine A Janeway
Journal:  Hematol Oncol Clin North Am       Date:  2009-02       Impact factor: 3.722

View more
  20 in total

Review 1.  Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome.

Authors:  Nikolaos Settas; Fabio R Faucz; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2017-07-21       Impact factor: 4.102

Review 2.  Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Authors:  Pushpa Neppala; Sudeep Banerjee; Paul T Fanta; Mayra Yerba; Kevin A Porras; Adam M Burgoyne; Jason K Sicklick
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

3.  Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs?

Authors:  Toshirou Nishida
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-16

4.  Understanding the critical role for surgery in the management of wild-type gastrointestinal stromal tumor (GIST).

Authors:  Bradford J Kim; Joshua K Kays; Leonidas G Koniaris; Nakul P Valsangkar
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-15

5.  Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors.

Authors:  Israel Fernandez-Pineda; Bhaskar N Rao
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

6.  The Call of "The Wild"-Type GIST: It's Time for Domestication.

Authors:  Maha Alkhuziem; Adam M Burgoyne; Paul T Fanta; Chih-Min Tang; Jason K Sicklick
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

7.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

Review 8.  Pediatric gastrointestinal stromal tumors-a review of diagnostic modalities.

Authors:  Hallie J Quiroz; Brent A Willobee; Matthew S Sussman; Bradley R Fox; Chad M Thorson; Juan E Sola; Eduardo A Perez
Journal:  Transl Gastroenterol Hepatol       Date:  2018-08-08

Review 9.  Current treatment strategies in pediatric gastrointestinal stromal cell tumor.

Authors:  Brent A Willobee; Hallie J Quiroz; Matthew S Sussman; Chad M Thorson; Juan E Sola; Eduardo A Perez
Journal:  Transl Gastroenterol Hepatol       Date:  2018-08-08

Review 10.  Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency.

Authors:  Georgia Pitsava; Nikolaos Settas; Fabio R Faucz; Constantine A Stratakis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-03       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.